Clinical Trials Logo

Metabolic Diseases clinical trials

View clinical trials related to Metabolic Diseases.

Filter by:

NCT ID: NCT05244785 Completed - Nutrition, Healthy Clinical Trials

Health and Nutrition Survey on Shenzhen Children

Start date: October 20, 2021
Phase:
Study type: Observational

1. Master and analyze the nutritional health, growth and development status of primary and secondary school students in Shenzhen, and discover the main nutritional health, growth and development problems and influencing factors. 2. Provide basic data and evidence-based basis for the municipal government and related departments to formulate child health policies and measures.

NCT ID: NCT05238012 Completed - Clinical trials for Metabolism Disorder, Glucose

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

XTREME
Start date: August 2, 2022
Phase: Phase 4
Study type: Interventional

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes

NCT ID: NCT05210530 Completed - Diabetes Mellitus Clinical Trials

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D

NCT ID: NCT05189353 Completed - Clinical trials for Bariatric Surgery Candidate

The Importance of Ghrelin for Glucose Metabolism After Sleeve Gastrectomy

Start date: January 14, 2022
Phase: N/A
Study type: Interventional

The overall aim is to delineate the contribution of ghrelin to glucose tolerance after sleeve gastrectomy. The hypothesis is that decreased concentration of ghrelin after SG is of importance for improved insulin secretion and glucose tolerance seen after SG. The expectation is therefore that infusion of ghrelin will impair insulin secretion and glucose tolerance compared with a control day without ghrelin infusion.

NCT ID: NCT05174104 Completed - Sleep Disorder Clinical Trials

Metabolic and Chronobiological Changes in Vestibular Rehabilitation

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the impact of vestibular rehabilitation on metabolic aspects when evaluated by means of bioelectrical impedenzometry analysis, smart watch device and actigraphy in a group of vestibular hypofunction patients previously studied by means of video head impulse test, posturography and clinical validated scales

NCT ID: NCT05172180 Completed - COVID-19 Clinical Trials

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

CARECOVID
Start date: December 1, 2020
Phase:
Study type: Observational

Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection. An observational prospective study included 105 patients with a severe course of novel coronavirus infection

NCT ID: NCT05161182 Completed - Clinical trials for Postprandial Hyperglycemia

Westlake N-of-1 Trials for Macronutrient Intake 2 ( WE-MACNUTR 2)

Start date: October 30, 2021
Phase: N/A
Study type: Interventional

Diet and nutrition are key to maintain human health. Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) trial investigates individualized postprandial glycemic responses to different proportions of dietary fat and carbohydrates intake using an n-of-1 experimental study design. The experimental diets are isocaloric high fat, low carbohydrate (HF-LC) or low fat, high carbohydrate (LF-HC). With standardized intervention and strictly controlled eating behaviors, the WE-MACNUTR study identifies specific HC-responders and HF-responders in terms of postprandial glucose response. This is a follow-up study offered to participants who have completed the WE-MACNUTR study in 2019. Volunteers will be asked to participate in four 5-d periods while wearing glucose monitors (Abbott Freestyle Libre) with the following experimental sequence: 1) a washout diet, 2) HF-LC or LC-HF diet, 3) a washout diet, 4) HF-LC or LC-HF diet. The experimental diet will be randomly assigned. Participants will be asked to provide a fasted blood sample and to collect fecal, urine and saliva samples at each visits.

NCT ID: NCT05139264 Completed - Clinical trials for Metabolism Disorder, Glucose

Glucose, Activity, Diet, & Sleep Assessment Study

GLADS
Start date: May 3, 2021
Phase:
Study type: Observational

GLADS is a cross-sectional, observational study assessing free-living diet, physical activity, sleep, and glucose profile over a 2-week period in healthy adult men and women.

NCT ID: NCT05137990 Completed - Clinical trials for Overweight and Obesity

The HIIT Cognition Study

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This pilot study is a randomized control trial to test the effects of a 14-week home-based virtual, interactive high intensity interval training (HIIT) exercise intervention on cardiometabolic and cognitive outcomes in sedentary youth with overweight/obesity during adolescence. All participants (N=24) will complete screening via phone to determine eligibility. Eligible participants will be randomized to receive a) 14 weeks of a home-based HIIT intervention delivered via iPad or b) 14 weeks of a stretching intervention (control group). Each participant will undergo an in-lab pre- and post-test visit, where they will complete a fasting blood draw, a fitness test, and various cognitive and mental health measures.

NCT ID: NCT05023499 Completed - Cachexia Clinical Trials

Perioperative Glutamine Supplementation and Cachexia

Start date: January 1, 2016
Phase:
Study type: Observational

Background Sarcopenia is characterized by the degenerative loss of skeletal muscle and is associated with increased adverse surgical outcomes. Glutamine is considered as an immune-modulating formula, which may stimulate protein synthesis in the skeletal muscle but also inhibited protein-degradation. In this study, the investigators calculate the area and volume psoas major muscle (PMMA; PMMV) of the third lumbar vertebral body as the reference of skeletal muscle. The aim of this study is to investigate whether perioperative glutamine supplementation restores atrophy of psoas muscle.